ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice ...
ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Australian biotechnology ...
BRUSSELS, June 20 (Reuters) - EU antitrust regulators are investigating whether Vifor Pharma (VIFN.S), opens new tab, which is being acquired by CSL Ltd (CSL.AX), opens new tab, disparaged its rival ...
Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settlement agreements with Mylan Laboratories Ltd., and Sandoz, Inc., ...
Orbicular Pharmaceutical Technologies was hit with a patent infringement lawsuit on Oct. 20 in New Jersey District Court over its planned generic version of the iron deficiency drug Injectafer. The ...
Thinly traded nano cap ChemoCentryx (NASDAQ:CCXI) is up 81% premarket on robust volume in response to its announcement of a collaboration and license agreement with Vifor Pharma to commercialize lead ...
LONDON/ZURICH, Nov 27 (Reuters) - Swiss drugmaker Vifor Pharma (VIFN.S), opens new tab had a recent takeover approach from at least one private equity firm, but talks were halted due to differences ...
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback